海翔药业：获得地夸磷索钠化学原料药上市申请批准

Core Viewpoint - The approval of the sodium diquafosol raw material drug by the National Medical Products Administration enhances the company's product pipeline and competitiveness, although it will not have a significant short-term impact on performance due to pending GMP inspections and various uncertainties regarding production and sales timing [1] Group 1 - The company has received the approval notice for the sodium diquafosol raw material drug, which is packaged in 5kg barrels and meets drug registration requirements [1] - Sodium diquafosol is a P2Y2 receptor agonist, and its eye drops are used for the treatment of dry eye syndrome, with projected sales of 130.89 million yuan in public hospitals in Chinese cities in 2024 [1] - The approval will enrich the company's product pipeline and enhance its competitiveness in the market [1] Group 2 - The company still needs to pass GMP inspections, which introduces uncertainty regarding the short-term impact on performance [1] - The timing and conditions of production and sales are influenced by multiple factors, leading to further uncertainties [1]